Company Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases.
The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution.
In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles.
The company is headquartered in Salt Lake City, Utah.
| Country | United States |
| Founded | 2012 |
| Industry | Packaged Foods |
| Sector | Consumer Staples |
| Employees | 85 |
| CEO | Robert Etherington |
Contact Details
Address: 6550 South Millrock Drive, Suite G50 Salt Lake City, Utah 84121 United States | |
| Phone | 801 676 9695 |
| Website | clene.com |
Stock Details
| Ticker Symbol | CLNN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001822791 |
| CUSIP Number | 185634102 |
| ISIN Number | US1856341029 |
| Employer ID | 85-2828339 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert Etherington MBA | Chief Executive Officer, President and Director |
| Morgan R. Brown CPA, M.B.A. | Chief Financial Officer |
| Mark G. Mortenson ESQ. | Chief Science Officer |
| Jerry Miraglia J.D. | General Counsel and Corporate Secretary |
| Michael T. Hotchkin | Chief Development Officer |
| Mary Anne Mcneil | Head of Human Resources |
| Dr. Benjamin M. Greenberg M.D., M.H.S. | Head of Medical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 23, 2024 | 8-K | Current Report |
| Oct 9, 2024 | D | Notice of Exempt Offering of Securities |
| Oct 2, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 2, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |